ASK1 inhibitor attenuated cardiac hypertrophy and cardiorenal fibrosis induced by IS and PCS, and may be a beneficial therapeutic agent to decelerate CRS progression mediated by uremic toxins. This evidence concerns the gene MAP3K5 and cardiac hypertrophy.